Insider · CIK 0001614741
Eric Lefebvre
Files at CBAY (CymaBay Therapeutics, Inc.), PLRX (PLIANT THERAPEUTICS, INC.). First filing Jan 19, 2024, latest Jul 12, 2024.
In brief
Eric Lefebvre files SEC Form 4 as director and officer at PLRX (PLIANT THERAPEUTICS, INC.), and also at CBAY (CymaBay Therapeutics, Inc.). Since Jan 19, 2024, Eric Lefebvre has reported 0 open-market buys worth $0 and 2 open-market sells worth $320k, the latest filed on Jul 12, 2024.
A track record needs three past buys with six months of prices behind them; Eric Lefebvre has 0, so none is measured yet.
The newest scored trade: sold $142k of PLRX on Jul 10, 2024, filed Jul 12, 2024, scored 21 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PLRX: PLIANT THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | PLIANT THERAPEUTICS, INC. | $142k 12,319 shares | -5% | +5% from low-45% from high | |
| 22Weak | PLIANT THERAPEUTICS, INC. | $177k 10,295 shares | -6% | +39% from low-51% from high |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2024 | PLRX PLIANT THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -12,319 | $11.56 | $142k | 213,052 | Jul 12, 2024 |
| Jul 9, 2024 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Common Stock | +24,063 | $0.00 | $0 | 225,371 | Jul 11, 2024 |
| Mar 22, 2024 | CBAY CymaBay Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -115,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | CBAY CymaBay Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | CBAY CymaBay Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,010 | - | - | 0 | Mar 22, 2024 |
| Jan 24, 2024 | CBAY CymaBay Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +14,010 | $0.00 | $0 | 14,010 | Jan 26, 2024 |
| Jan 23, 2024 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Common Stock | +42,900 | $0.00 | $0 | 199,820 | Jan 24, 2024 |
| Jan 23, 2024 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +85,800 | $0.00 | $0 | 85,800 | Jan 24, 2024 |
| Jan 17, 2024 | PLRX PLIANT THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -10,295 | $17.23 | $177k | 156,920 | Jan 19, 2024 |
Questions about Eric Lefebvre
Answered from the filings on this page, as of the latest one.
Is Eric Lefebvre buying or selling?
Not in the last 12 months. Eric Lefebvre's latest open-market trade on SEC Form 4 was sold $142k of PLRX on Jul 10, 2024.
How did Eric Lefebvre's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Eric Lefebvre has 0.
Where does Eric Lefebvre file Form 4?
Eric Lefebvre has filed Form 4 at PLRX (PLIANT THERAPEUTICS, INC.) as Chief Medical Officer; CBAY (CymaBay Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.